Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TuHURA Biosciences, Inc./NVKTRA · Entity 6601 | Director · SVP, Business Development | September 15, 2020 | September 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TuHURA Biosciences, Inc./NV
Report date September 15, 2020 · Filed September 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2030-09-15 | Direct | 506,647 |
Reported balance
After 2020-09-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 506,647 · Balance 506,647 F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 18, 2020 01:09 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 506,647 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000973 · kintara_fm4sep152020.xml · derivative · entry 1 Liatos John · CIK 0001821508 · Director · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,647 Underlying: Common Stock · 506,647 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:17 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | PurchaseCommon Stock | 196,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-023272 · ownership.xml · nonDerivative · entry 1 Liatos John · CIK 0001821508 · Director · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,750 F1 · price: Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.